Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
Schizophrenia, Schizoaffective Disorder, Social Anxiety Disorder
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, Schizoaffective Disorder, Social Anxiety Disorder
Eligibility Criteria
Inclusion Criteria Patients meeting DSM IV diagnostic criteria for schizophrenia or schizoaffective disorder. Patients presenting with comorbid social anxiety symptoms of moderate to high severity are eligible for participation in the study. Only patients with LSAS scores above 30* qualify for the study. Age 18-65 Gender: males or females Females: non-pregnant, not of child-bearing potential; if of child-bearing age must be on contraceptive such as pill or shot (condom alone not sufficient) Good general health Exclusion Criteria: Patient does not meet DSM IV diagnostic criteria for schizophrenia or schizoaffective disorder Patient carries a diagnosis of dementia, degenerative CNS disorders, mental retardation, substance abuse or dependence other than nicotine dependence or alcohol abuse will be excluded from the study. Patients with acute medical conditions are not eligible. Patients allergic or otherwise intolerant or non-responsive to Aripiprazole Patient with history of suicidal, homicidal or assaultive plans or attempts in the past 6 months. Clinically significant EKG or lab abnormalities
Sites / Locations
- Robert Wood Johnson Medical School - Psychiatry Dept.